Neumora Therapeutics, Inc. Common Stock (NMRA) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Jason G. Duncan	Chief Legal & Administrative Officer	315,000	1974
Daljit Singh Aurora	Chief Operationg and development officer	1.75M	1968
Joshua Pinto	President	2.1M	1985
Paul Yeung	Senior Vice President of Clinical Development	0	N/A
Stefan Bluemmers	Senior VP of Business Development & Portfolio Management	0	N/A
Michael Lee Milligan	Chief Financial Officer & Principal Accounting Officer	0	1973
Carol Suh	Co-Founder & Chief Strategy Officer	0	1989
Pablo Gersberg	Chief Information Officer	0	N/A
Amy Sullivan	Chief Human Resources Officer	0	N/A
Nicholas Brandon	Chief Scientific Officer	0	1975
Lori Houle	Chief Technical Operations & Quality Officer	0	1967
Helen Rubinstein	Head of Investor Relations	0	N/A

Name

Title

Pay

Year Born

Jason G. Duncan

Chief Legal & Administrative Officer

315,000

1974

Daljit Singh Aurora

Chief Operationg and development officer

1.75M

1968

Joshua Pinto

President

2.1M

1985

Paul Yeung

Senior Vice President of Clinical Development

N/A

Stefan Bluemmers

Senior VP of Business Development & Portfolio Management

N/A

Michael Lee Milligan

Chief Financial Officer & Principal Accounting Officer

1973

Carol Suh

Co-Founder & Chief Strategy Officer

1989

Pablo Gersberg

Chief Information Officer

N/A

Amy Sullivan

Chief Human Resources Officer

N/A

Nicholas Brandon

Chief Scientific Officer

1975

Lori Houle

Chief Technical Operations & Quality Officer

1967

Helen Rubinstein

Head of Investor Relations

N/A

Description

Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.